 |
|
Statins and the Risk of Cancer
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: We are concerned that in the meta-analysis of statin use and cancer by Dr Dale and colleagues1 the periods of follow-up and of statin use in the randomized controlled trials (RCTs) are too brief to have captured a true association between statin use and cancer risk or mortality. For prostate cancer and several other cancers analyzed in the meta-analysis, there is a well-recognized and often extended latency time between the initiation of cancer and clinical detection.2 Although the median age at initial prostate cancer diagnosis is 69 years in the United States,3 autopsy studies have shown that prostatic intraepithelial neoplasia, a potential premalignant precursor, and histologic prostate cancer are evident in the third and fourth decades of life.4-5 Thus, the critical period of cancer initiation likely occurred long before the time period evaluated in the statin RCTs for most of the prostate cancers observed in RCT participants. . . . [Full Text of this Article]
Claudia A. Salinas, MS;
Ilir Agalliu, MD, ScD;
Janet L. Stanford, PhD
jstanfor@fhcrc.org
Division of Public Health Sciences
Fred Hutchinson Cancer Research Center
Seattle, Wash
Daniel W. Lin, MD
Department of Medicine
University of Washington
Seattle
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Statin Use and Risk of Prostate Cancer: Results from a Population-based Epidemiologic Study
Agalliu et al.
Am J Epidemiol 2008;168:250-260.
ABSTRACT
| FULL TEXT
Statin Induces Apoptosis and Cell Growth Arrest in Prostate Cancer Cells
Hoque et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:88-94.
ABSTRACT
| FULL TEXT
Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer
Platz
Cancer Epidemiol. Biomarkers Prev. 2007;16:2175-2180.
FULL TEXT
|
